Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical ...

MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.

Alvotech ALVO, a commercial-stage company developing and manufacturing biosimilar medicines for patients worldwide, is ...

Q2 2025 Earnings Call Transcript July 29, 2025 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.13, expectations were $2.03. Operator: Thank you for standing by. Welcome to the Merck ...

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build ...

The multi-national that has a plant at Ballydine near Kilsheelan is making the global cutbacks as it prepares for generic ...

Bain Capital will make a $300 million funding in the new company, while BMY will out-license five immunology candidates.

This month, Trump threatened 200% tariffs on imported medicines. Last weekend, he agreed to a much lower 15% tariff on ...

In July 2025, Marengo Therapeutics Inc. organized a phase 1/2 study to assess the safety/tolerability and preliminary ...